Cognition Therapeutics Inc (CGTX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
(Values in U.S. thousands)
| 12-2025 | 12-2024 | 12-2023 | 12-2022 | 12-2021 | |
| Cash Flows From Operating Activities | |||||
| Net Income | -23,487 | -33,971 | -25,788 | -21,397 | -11,716 |
| Depreciation Amortization | 228 | 266 | 252 | 235 | 476 |
| Accounts receivable | -7,237 | -1,405 | 2,391 | -1,406 | -1,114 |
| Accounts payable and accrued liabilities | 3,510 | 1,854 | 2,440 | -749 | 2,165 |
| Other Working Capital | -3,457 | 1,288 | 4,846 | -943 | 2,842 |
| Other Operating Activity | 5,855 | 3,494 | -159 | 5,727 | 3,716 |
| Operating Cash Flow | $-24,588 | $-28,474 | $-16,018 | $-18,533 | $-3,631 |
| Cash Flows From Investing Activities | |||||
| PPE Investments | 9 | -4 | -147 | -171 | -27 |
| Investing Cash Flow | $9 | $-4 | $-147 | $-171 | $-27 |
| Cash Flows From Financing Activities | |||||
| Debt Issued | N/A | N/A | N/A | N/A | 8,942 |
| Common Stock Issued | 37,087 | 24,432 | 5,332 | 6,942 | 44,527 |
| Other Financing Activity | -517 | -867 | -811 | -1,396 | -268 |
| Financing Cash Flow | $36,570 | $23,565 | $4,521 | $5,546 | $53,201 |
| Exchange Rate Effect | N/A | N/A | 4 | -1 | -11 |
| Beginning Cash Position | 25,009 | 29,922 | 41,562 | 54,721 | 5,189 |
| End Cash Position | 37,000 | 25,009 | 29,922 | 41,562 | 54,721 |
| Net Cash Flow | $11,991 | $-4,913 | $-11,640 | $-13,159 | $49,532 |
| Free Cash Flow | |||||
| Operating Cash Flow | -24,588 | -28,474 | -16,018 | -18,533 | -3,631 |
| Capital Expenditure | N/A | -4 | -147 | -171 | -27 |
| Free Cash Flow | -24,588 | -28,478 | -16,165 | -18,704 | -3,658 |